(1) Background: The current limitations of glioblastoma (GBM) chemotherapy were
addressed by developing a molecularly imprinted polymer (MIP)-based drug reservoir …

Purpose: Recently, polymeric controlled delivery of chemotherapy has been shown to
improve survival of patients with malignant glioma. We evaluated whether we could similarly …

Introduction Polymer-based delivery systems offer innovative intra-cavity administration of
drugs, with the potential to better target micro-deposits of cancer cells in brain parenchyma …

Background Recently, polymeric controlled delivery of chemotherapy has been shown to
improve survival of patients with malignant glioma. We tested the delivery of IUdR via …

Simple Summary This study reports a potential new drug—Cerebraca wafer—that is
designed to deliver its active pharmaceutical ingredient,(Z)-n-butylidenephthalide (BP) …

The third-generation of EGFR-TKI osimertinib has been approved as a first-line therapy in
NSCLC, representing the most successful advance in molecularly targeted therapy …

Introduction Surgical resection and systemic chemotherapy with temozolomide remain the
mainstay for treatment of glioblastoma. However, many patients are not candidates for …

Glioblastoma multiforme (GBM) is the most common form of primary brain cancer and has
the highest morbidity rate and current treatments result in a bleak 5-year survival rate of …

Vascular normalisation refers to a 'remodeling'of the dysfunctional tumour capillary network,
which regresses under the influence of anti-VEGF treatment, resulting in improved blood …

Local implant-based delivery of rationally selected combination of chemotherapeutics has
some major advantages for the treatment of glioblastoma such as:(a) 100% bio-availability …